Parabilis Medicines (NASDAQ:PBLS) Announces Quarterly Earnings Results

Parabilis Medicines (NASDAQ:PBLS – Get Free Report) issued its earnings results on Thursday. The company reported ($0.36) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.04, FiscalAI reports. The firm had revenue of $2.11 million for the quarter.

Parabilis Medicines Stock Performance

NASDAQ:PBLS traded down $0.21 during midday trading on Friday, hitting $27.48. The company’s stock had a trading volume of 111,348 shares, compared to its average volume of 808,214. The company’s 50 day simple moving average is $31.11. The company has a market capitalization of $3.39 billion and a price-to-earnings ratio of -12.90. Parabilis Medicines has a fifty-two week low of $22.66 and a fifty-two week high of $42.49.

Analyst Upgrades and Downgrades

A number of research analysts have commented on PBLS shares. HC Wainwright assumed coverage on shares of Parabilis Medicines in a research report on Thursday, October 22nd. They set a “buy” rating and a $40.00 target price on the stock. Weiss Ratings downgraded shares of Parabilis Medicines from a “sell (d+)” rating to a “sell (d)” rating in a research note on Monday, November 2nd. Finally, Canaccord Genuity Group started coverage on shares of Parabilis Medicines in a report on Monday. They set a “buy” rating and a $39.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Parabilis Medicines has an average rating of “Moderate Buy” and a consensus price target of $40.80.

View Our Latest Analysis on Parabilis Medicines

Institutional Investors Weigh In On Parabilis Medicines

A number of hedge funds and other institutional investors have recently made changes to their positions in PBLS. Sterling Capital Management LLC purchased a new stake in shares of Parabilis Medicines during the 3rd quarter worth about $35,000. Parallel Advisors LLC grew its position in shares of Parabilis Medicines by 95.5% in the third quarter. Parallel Advisors LLC now owns 1,075 shares of the company’s stock valued at $35,000 after purchasing an additional 525 shares in the last quarter. Russell Investments Group Ltd. acquired a new stake in shares of Parabilis Medicines in the 3rd quarter worth $96,000. Persistent Asset Partners Ltd acquired a new position in Parabilis Medicines in the 2nd quarter valued at about $113,000. Finally, Voya Investment Management LLC purchased a new position in Parabilis Medicines in the third quarter worth approximately $241,000.

About Parabilis Medicines

(Get Free Report)

Parabilis Medicines is a clinical-stage biopharmaceutical company developing medicines for diseases driven by proteins that have been difficult to target with conventional drugs. Its research focuses on macrocyclic peptides designed to address challenging protein interactions, including targets relevant to cancer. The company uses its proprietary Helicon platform to design these peptide-based drug candidates. Parabilis is based in Cambridge, Massachusetts, and was formerly known as Peptone. Parabilis was founded by Gregory Verdine, who serves as the company’s chief executive officer.

Featured Stories

Receive News & Ratings for Parabilis Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Parabilis Medicines and related companies with MarketBeat.com's FREE daily email newsletter.